Unique ID issued by UMIN | UMIN000004201 |
---|---|
Receipt number | R000005048 |
Scientific Title | The evaluation of efficacy for remission maintenance with immunomodulator following remission induction with tacrolimus in patients with moderate to severe active refractory ulcerative colitis.:mucosal healing for prognosis |
Date of disclosure of the study information | 2010/09/14 |
Last modified on | 2024/03/10 22:28:06 |
The evaluation of efficacy for remission maintenance with immunomodulator following remission induction with tacrolimus in patients with moderate to severe active refractory ulcerative colitis.:mucosal healing for prognosis
Hyogo College of Medicine, Osaka Medical College, Osaka City University Project 1, Tacrolimus-Ulcerative Colitis, 3 [Mucosal Healing for Prognosis]
: HOOP1 (TCL-UC)-3 [MHP]
The evaluation of efficacy for remission maintenance with immunomodulator following remission induction with tacrolimus in patients with moderate to severe active refractory ulcerative colitis.:mucosal healing for prognosis
Hyogo College of Medicine, Osaka Medical College, Osaka City University Project 1, Tacrolimus-Ulcerative Colitis, 3 [Mucosal Healing for Prognosis]
: HOOP1 (TCL-UC)-3 [MHP]
Japan |
The patients with moderate to severe active refractory ulcerative colitis
Gastroenterology |
Others
NO
The evaluation of efficacy for remission maintenance with immunomodulator following remission induction with tacrolimus in patients with moderate to severe active refractory ulcerative colitis.
Efficacy
Remission rate at 48 weeks after the administration of tacrolimus
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
No treatment
2
Treatment
Medicine |
Group of remission maintenance therapy for 48 weeks with immunomodulator at from 2 to 4 weeks following remission induction with tacrolimus,
Group of no remission maintenance therapy with immunomodulator following remission induction with tacrolimus,
16 | years-old | <= |
65 | years-old | > |
Male and Female
1)The patients with ulcerative colitis of left side colitis or pancolitis type
2)Moderate to severe active ulcerative colitis (more than 6 points for DAI)
3)Steroid refractory or dependent case
1)The treatment with immunomodulator or anti-TNF alpha agents within 12 weeks before administration of tacrolimus
2)The treatment with cytapheresis within 12 weeks before administration of tacrolimus
3)The patients who are not suitable for treatment of immunomodulator
4)The patients after colectomy
5)the patients with renal disorder
50
1st name | Kenji |
Middle name | |
Last name | Watanabe |
Osaka City University, Graduate School of Medicine
Gastroenterology
545-8585
1-4-3, Asahi-machi, Abeno-ku, Osaka
0666453811
kenjiw1779@gmail.com
1st name | Kenji |
Middle name | |
Last name | Watanabe |
Osaka City University, Graduate School of Medicine
Gastroenterology
545-8585
1-4-3, Asahi-machi, Abeno-ku, Osaka
0666453811
kenjiw1779@gmail.com
Osaka City University, Graduate School of Medicine,Department of Gastroenterology
None
Self funding
Ethical Committee of Osaka City University, Graduate School of Medicine
1-4-3, Asahi-machi, Abeno-ku, Osaka
06-6646-6125
kenjiw1779@gmail.com
YES
1772
Ethical Committee of Osaka City University, Graduate School of Medicine
大阪市立大学病院(大阪府)、兵庫医科大学病院(兵庫県)、大阪医科大学病院(大阪府)
2010 | Year | 09 | Month | 14 | Day |
Unpublished
Completed
2013 | Year | 08 | Month | 29 | Day |
2010 | Year | 06 | Month | 08 | Day |
2013 | Year | 12 | Month | 02 | Day |
2017 | Year | 03 | Month | 31 | Day |
2010 | Year | 09 | Month | 14 | Day |
2024 | Year | 03 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005048